Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.
Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.